Treatment of Alzheimer's disease with sabeluzole: functional and structural correlates - PubMed (original) (raw)
Clinical Trial
Treatment of Alzheimer's disease with sabeluzole: functional and structural correlates
E Mohr et al. Clin Neuropharmacol. 1997 Aug.
Abstract
Sabeluzole, a new benzothiazole derivative, has been shown to be neurobiologically active preclinically and clinically appears to exert beneficial effects on memory. In this study, sabeluzole (5 or 10 mg twice daily vs. placebo) was investigated in patients with probable Alzheimer's disease over 1 year, with assessments of cognitive performance and structural changes. Cognitive performance was measured using the Alzheimer's Disease Assessment Scale periodically during treatment. Potential structural correlates in the frontal horn, caudate, third ventricle and hippocampal regions were examined by obtaining computerized tomographic (CT) images before and after treatment. Patients receiving sabeluzole evidenced greater stability than did placebo-treated patients in some cognitive measures. CT measures showed no significant changes from baseline, but some weak associations were found between relative preservation of cognitive function and smaller structural declines in the third ventricle and hippocampus. Cognitive outcome measures suggest that sabeluzole may have potential in slowing the cognitive deterioration of Alzheimer's disease. Furthermore, the method used to explore potential benefits on a morphologic level, although negative in this study, could yet have potential.
Similar articles
- Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease.
Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, Ieni JR, Rogers S. Krishnan KR, et al. Am J Psychiatry. 2003 Nov;160(11):2003-11. doi: 10.1176/appi.ajp.160.11.2003. Am J Psychiatry. 2003. PMID: 14594748 Clinical Trial. - Effect of sabeluzole (R 58,735) on memory functions in patients with epilepsy.
Aldenkamp AP, Overweg J, Smakman J, Beun AM, Diepman L, Edelbroek P, Gutter T, Mulder OG, vt Slot B, Vledder B. Aldenkamp AP, et al. Neuropsychobiology. 1995;32(1):37-44. doi: 10.1159/000119210. Neuropsychobiology. 1995. PMID: 7566521 Clinical Trial. - APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.
Aerssens J, Raeymaekers P, Lilienfeld S, Geerts H, Konings F, Parys W. Aerssens J, et al. Dement Geriatr Cogn Disord. 2001 Mar-Apr;12(2):69-77. doi: 10.1159/000051238. Dement Geriatr Cogn Disord. 2001. PMID: 11173877 - Donepezil for mild and moderate Alzheimer's disease.
Birks J S, Melzer D. Birks J S, et al. Cochrane Database Syst Rev. 2000;(2):CD001190. doi: 10.1002/14651858.CD001190. Cochrane Database Syst Rev. 2000. PMID: 10796620 Updated. Review. - Donepezil for vascular cognitive impairment.
Malouf R, Birks J. Malouf R, et al. Cochrane Database Syst Rev. 2004;(1):CD004395. doi: 10.1002/14651858.CD004395.pub2. Cochrane Database Syst Rev. 2004. PMID: 14974068 Review.
Cited by
- Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?
Becker RE, Greig NH, Giacobini E. Becker RE, et al. J Alzheimers Dis. 2008 Oct;15(2):303-25. doi: 10.3233/jad-2008-15213. J Alzheimers Dis. 2008. PMID: 18953116 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical